Antitrust and Merger Control — A Practitioner Overview

Merger control refers to the regulatory oversight process by which competition authorities review proposed mergers, acquisitions, and joint ventures to assess their potential impact on market competition. The objective is to prevent transactions that could substantially lessen competition, lead to monopolies, or otherwise harm consumers and market participants. For M&A practitioners, understanding the jurisdictional triggers, substantive review standards, and procedural aspects across key regimes is paramount to effective deal execution and risk management.

Transactions meeting specific thresholds almost invariably require pre-merger notification and approval from relevant competition authorities. These thresholds typically involve turnover (revenue) of the transacting parties, sometimes combined with market share criteria or the value of the transaction itself. The determination of which jurisdictions assert authority over a given transaction is often complex, requiring a detailed analysis of the parties' global operations and sales allocations. A single transaction may trigger parallel reviews in multiple jurisdictions, each with its own set of rules, timelines, and potential for intervention. The strategic implications of multi-jurisdictional filings, including sequencing and coordination, represent a critical element of pre-deal planning.

Jurisdictional Reach and Thresholds in Key Regimes

The European Union's merger control framework, primarily governed by the EU Merger Regulation (EUMR), is characterized by its broad reach. The EUMR employs turnover-based thresholds to determine jurisdiction. There are two primary sets of thresholds: a general EU-wide threshold and an alternative set for cases with a significant presence in multiple Member States but not necessarily meeting the pan-EU threshold. The core EUMR thresholds require notification if the combined aggregate worldwide turnover of all the undertakings concerned is more than €5 billion, and at least two of the undertakings concerned each have an EU-wide turnover of more than €250 million. However, if the EU-wide thresholds are not met, jurisdiction can still be triggered if the combined aggregate worldwide turnover is more than €2.5 billion, the combined aggregate turnover in each of at least three Member States is more than €100 million, in each of at least three Member States the aggregate turnover of each of at least two undertakings concerned is more than €25 million, and the aggregate EU-wide turnover of each of at least two of the undertakings is more than €100 million. The 'one-stop shop' principle generally means that if the EUMR applies, Member State national competition authorities are precluded from reviewing the same transaction, simplifying the process for businesses. However, referral mechanisms exist, both from the EU to Member States and vice versa.

In the United Kingdom, following Brexit, the Competition and Markets Authority (CMA) now operates an independent merger control regime. The UK regime is primarily voluntary but features robust investigatory powers, allowing the CMA to review transactions even if parties do not formally notify. Jurisdictional thresholds are typically met if the target company's UK turnover exceeds £70 million or if the transaction leads to or enhances a 25% share of supply or purchase of goods or services of a particular description in the UK (or a substantial part of the UK). The share of supply test is particularly broad and can capture transactions involving relatively small targets if market concentration is high. The CMA also has a 'small merger safe harbour' for transactions where the target's UK turnover is less than £10 million, though this has caveats. The UK's approach has been increasingly active, extending to transactions with limited direct UK-nexus but potential competitive effects within its borders, particularly in digital markets, prompting a focus on 'killer acquisitions' and nascent competition concerns.

The US Regulatory Landscape: HSR Act and Enforcement

In the United States, merger control is primarily governed by the Hart-Scott-Rodino (HSR) Antitrust Improvements Act of 1976. The HSR Act requires parties to certain mergers and acquisitions to notify the Federal Trade Commission (FTC) and the Department of Justice (DOJ) before closing the transaction. The thresholds for HSR notification are revised annually, typically in late January/early February, and are based on the 'size of transaction' and 'size of person' tests. For 2023, for example, the 'size of transaction' threshold generally requires notification if, as a result of the acquisition, the acquiring person will hold voting securities, assets, or non-corporate interests of the acquired person valued at more than $111.4 million. If the transaction value exceeds $445.5 million, the 'size of person' test is generally not applicable, meaning even a small party can be involved. Below $445.5 million but above $111.4 million, the 'size of person' test applies, requiring one party to have annual net sales or total assets of at least $222.7 million and the other party to have annual net sales or total assets of at least $22.3 million. Certain exemptions apply, such as for acquisitions in the ordinary course of business or specific types of real property. The HSR process is characterized by statutory waiting periods (typically 30 days for most transactions, 15 days for all-cash tender offers and bankruptcies), during which the parties cannot close the deal. These waiting periods can be extended if either the FTC or DOJ issues a 'Second Request' for additional information, significantly prolonging the review.

Both the FTC and DOJ have distinct enforcement mandates. The FTC's jurisdiction includes a wide range of industries, while the DOJ's Antitrust Division typically focuses on criminal antitrust enforcement and specific sectors like telecommunications. While they share jurisdiction over merger review, they coordinate to avoid duplication, with one agency taking the lead on any given transaction. The substantive review in the US focuses on whether a transaction may 'substantially lessen competition' or 'tend to create a monopoly' in any line of commerce in any section of the country. This involves defining relevant product and geographic markets, assessing market concentration (often using the Herfindahl-Hirschman Index, or HHI), and evaluating potential anti-competitive effects such as coordinated interaction, unilateral effects, and barriers to entry.

Review Processes and Timelines: Phase I, Phase II, and Remedies

The review process in merger control typically proceeds in stages. In the EU, Phase I (initial investigation) usually lasts 25 working days from notification. During this period, the European Commission assesses whether a transaction raises serious doubts as to its compatibility with the common market. If no such doubts arise, the merger is cleared. If concerns are identified, the Commission can either accept commitments from the parties to alleviate these concerns (leading to a conditional Phase I clearance) or initiate Phase II proceedings. Phase II (in-depth investigation) is a much longer and more detailed review, typically lasting 90 working days, which can be extended under certain circumstances. During Phase II, the Commission conducts extensive market research, consults with customers and competitors, and may engage in detailed economic analysis. Parties often propose remedies during Phase II to secure approval.

The UK's CMA similarly has a two-phase merger review process. Phase 1 involves an initial assessment, typically lasting 40 working days from the date of the merger notice or the date the CMA begins its inquiry (if not formally notified). This phase determines whether there is a 'realistic prospect' of a 'substantial lessening of competition' (SLC) within any market in the UK. If such a prospect is identified, the CMA refers the case to a Phase 2 investigation unless the parties offer acceptable undertakings (remedies) to address the concerns. Phase 2 investigations are more extensive, normally taking up to 24 weeks, though this can be extended. During Phase 2, an independent group of panel members scrutinizes the merger in detail, consulting widely and often commissioning expert reports. The outcome can be an unconditional clearance, a conditional clearance based on remedies, or a prohibition of the merger.

Remedies are central to mitigating competition concerns identified by authorities. These can be structural (e.g., divestiture of specific business units, assets, or intellectual property), behavioral (e.g., commitments regarding pricing, access to infrastructure, or non-discrimination), or a combination thereof. Divestitures are generally favored by authorities as they are seen as more effective in restoring competition. The scope and complexity of remedies can significantly impact the financial and operational rationale of a deal, requiring careful evaluation during the negotiation and integration planning stages. The negotiation of remedies with regulatory bodies is often an iterative process, requiring deep market knowledge and strategic acumen.

Strategic Considerations and Managing Transaction Risk

Managing antitrust risk effectively requires a proactive, integrated approach throughout the M&A lifecycle. Early identification of potential competitive overlaps and market concentration issues during pre-deal due diligence is crucial. This involves not only analyzing product and geographic market definitions but also anticipating how regulators might view the transaction in light of their prevailing enforcement priorities. For instance, across the EU, UK, and US, there has been increasing scrutiny of transactions in digital markets, healthcare, and those involving nascent competitors or innovation concerns.

Strategic engagement with competition authorities, even on a pre-notification basis, can be beneficial. 'Pulling together' (i.e., informal discussions with regulators before formal filing) can help refine the scope of potential issues and understand agency concerns, potentially streamlining the formal review process. Sequencing of multi-jurisdictional filings also requires careful planning. While some jurisdictions allow for simultaneous filing, others may prefer or require a specific order, particularly when one jurisdiction's decision might influence others. Delays in one key jurisdiction can hold up global closing, impacting the entire transaction timeline and deal certainty.

Another critical consideration is the concept of 'gun-jumping.' This refers to the illegal pre-merger coordination or integration between merging parties before formal regulatory approval has been granted. Such actions can be seen as an early implementation of the transaction, violating standstill obligations and potentially incurring significant fines. Examples include sharing competitively sensitive information beyond what is necessary for due diligence or taking actions that could be construed as control over the target's business before closing. Clear internal protocols, clean teams for information exchange, and strict adherence to closing conditions are essential to avoid gun-jumping violations.

Ultimately, the effective management of antitrust and merger control risk is an integral part of successful M&A. It involves a cross-functional effort encompassing legal, economic, and strategic expertise. Practitioners must navigate a complex and evolving regulatory landscape, anticipate potential challenges, and develop robust strategies to secure necessary approvals while preserving deal value and certainty. The growing trend of increasingly interventionist competition authorities across major jurisdictions underscores the importance of this discipline in contemporary M&A practice.